These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30091950)

  • 1. Does the risk of arterial hypertension increase in the course of triptorelin treatment?
    Palma L; Gaudino R; Cavarzere P; Antoniazzi F
    J Pediatr Endocrinol Metab; 2020 Mar; 33(3):449-452. PubMed ID: 30091950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triptorelin depot for the treatment of children 2 years and older with central precocious puberty.
    Bertelloni S; Mucaria C; Baroncelli GI; Peroni D
    Expert Rev Clin Pharmacol; 2018 Jul; 11(7):659-667. PubMed ID: 29957076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty.
    Klein K; Yang J; Aisenberg J; Wright N; Kaplowitz P; Lahlou N; Linares J; Lundström E; Purcea D; Cassorla F
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1241-1248. PubMed ID: 26887034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation.
    Martínez-Aguayo A; Hernández MI; Beas F; Iñiguez G; Avila A; Sovino H; Bravo E; Cassorla F
    J Pediatr Endocrinol Metab; 2006 Aug; 19(8):963-70. PubMed ID: 16995580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
    Carel JC; Blumberg J; Seymour C; Adamsbaum C; Lahlou N;
    Eur J Endocrinol; 2006 Jan; 154(1):119-24. PubMed ID: 16382000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arterial hypertension during treatment with triptorelin in a child with Williams-Beuren syndrome.
    Siomou E; Kosmeri C; Pavlou M; Vlahos AP; Argyropoulou MI; Siamopoulou A
    Pediatr Nephrol; 2014 Sep; 29(9):1633-6. PubMed ID: 24604705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triptorelin (Triptodur) for central precocious puberty.
    Med Lett Drugs Ther; 2018 Jan; 60(1537):7-8. PubMed ID: 29294465
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment.
    Salerno M; Di Maio S; Gasparini N; Mariano A; Macchia V; Tenore A
    Horm Res; 1998; 50(4):205-11. PubMed ID: 9838241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudotumour Cerebri Presentation in a Child Under the Gonadotropin-Releasing Hormone Agonist Treatment.
    Gül Ü; Kaçar Bayram A; Kendirci M; Hatipoğlu N; Okdemir D; Gümüş H; Kurtoğlu S
    J Clin Res Pediatr Endocrinol; 2016 Sep; 8(3):365-7. PubMed ID: 27087351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of luteinizing hormone-releasing hormone agonists on final height in luteinizing hormone-releasing hormone-dependent precocious puberty.
    Oerter KE; Manasco PK; Barnes KM; Jones J; Hill S; Cutler GB
    Acta Paediatr Suppl; 1993 Mar; 388():62-8; discussion 69. PubMed ID: 8329833
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined therapy with GnRH analog plus growth hormone in central precocious puberty.
    Pucarelli I; Segni M; Ortore M; Moretti A; Iannaccone R; Pasquino AM
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():811-20. PubMed ID: 10969926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
    Lanes R; Soros A; Jakubowicz S
    J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonistic and agonistic GnRH analogue treatment of precocious puberty: tracking gonadotropin concentrations in urine.
    Roth CL; Brendel L; Rückert C; Hartmann K
    Horm Res; 2005; 63(5):257-62. PubMed ID: 15995342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome.
    Nunez SB; Calis K; Cutler GB; Jones J; Feuillan PP
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5730-3. PubMed ID: 14671160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist.
    Oostdijk W; Rikken B; Schreuder S; Otten B; Odink R; Rouwé C; Jansen M; Gerver WJ; Waelkens J; Drop S
    Arch Dis Child; 1996 Oct; 75(4):292-7. PubMed ID: 8984913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of precocious puberty by GnRH agonists].
    Carel JC
    Ann Urol (Paris); 2005 Oct; 39 Suppl 3():S85-8. PubMed ID: 16302717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of triptorelin acetate vs triptorelin pamoate in the treatment of Central precocious puberty (CPP): a retrospective study.
    Lasorella S; Porto R; Iezzi ML; Pistone C; Marseglia GL; Verrotti A; Brambilla I
    Gynecol Endocrinol; 2020 Apr; 36(4):338-340. PubMed ID: 31441342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate.
    Zenaty D; Blumberg J; Liyanage N; Jacqz-Aigrain E; Lahlou N; Carel JC;
    Horm Res Paediatr; 2016; 86(3):188-195. PubMed ID: 27603324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central precocious puberty due to hypothalamic hamartoma in a 7-month-old infant girl.
    Rousso IH; Kourti M; Papandreou D; Tragiannidis A; Athanasiadou F
    Eur J Pediatr; 2008 May; 167(5):583-5. PubMed ID: 17541635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.